Sesen Bio Strengthens Executive Leadership Team as the Company Approaches the Potential Approval and Commercial Launch of Vicineum™
Retrieved on:
Wednesday, August 11, 2021
Research, Infectious Diseases, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, BLA, Industry, Therapy, US Foods, Health, Safety, Caregiver, Company, Bio, Patient, Emory University School of Law, Head, Toxicity, Food, Risk, Consultant, U.S. Securities and Exchange Commission, Ernst, Compliance, Epithelial cell adhesion molecule, Security (finance), Priority review, MENA, Cancer, Pseudomonas exotoxin, Private Securities Litigation Reform Act, COVID-19, Hikma Pharmaceuticals, Environment, Employment, Georgia, Villanova University, Antigen, Orexigen Therapeutics, Nasdaq, FDA, EIP, Marketing, Law, PDUFA, Culture, LLP, BCG, Management, Lease, Vaccine, Pharmaceutical industry, Vicineum™, Sesen Bio, VICINEUM™, SESEN BIO
Mr. Knighton joins Sesen Bio from TherapeuticsMD, where he served as Chief Compliance Officer and supported the launch of three products between 2018 and 2020.
Key Points:
- Mr. Knighton joins Sesen Bio from TherapeuticsMD, where he served as Chief Compliance Officer and supported the launch of three products between 2018 and 2020.
- In connection with the hiring of Mr. Knighton, Sesen Bio intends to grant a non-statutory stock option.
- Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer.
- Sesen Bio continues to monitor the rapidly evolving environment regarding the potential impact of the COVID-19 pandemic on the Company.